Combination Therapy With Semaglutide and Dapagliflozin reduces synergistically anthracycline-induced cardiotoxicity under hyperglycemia: implications in primary prevention of CTRCD in cancer patients with T2DM
Anno:
2025
Background: Hyperglycemia and advanced glycation end products (AGES) are key players of heart failure and atherosclerosis in patients with/without cancer through the stimulation of pro-inflammatory signaling. GLP-1 receptor agonists exerts cardiorenal benefits in patients with/without diabetes, proposing themselves as a new cardioprotective strategy in a broad patient setting, including…